No profile data available.
Vor Biopharma Inc. (VOR) is a healthcare company in the blood cancer treatment drugs industry, based in Boston, United States, with about 76 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$695.98 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.08 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. , Ltd.
Vor Biopharma reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.08 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Legend Biotech Corporation (LEGN), Sellas Life Sciences Group, Inc. (SLS), Ascentage Pharma Group International (AAPG), Kura Oncology, Inc. (KURA).